We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Batch n ° 2 of the Public Market Evaluation "Medico-economic Demonstrator IsereADOM" (CardIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03457623
Recruitment Status : Recruiting
First Posted : March 7, 2018
Last Update Posted : March 7, 2018
Conseil Départemental de l'Isère
Information provided by (Responsible Party):
University Hospital, Grenoble

Brief Summary:

The goal of this study is to evaluate the health and social benefit of innovative management - IsereADOM - versus conventional follow-up in patients with heart failure.

There is a medico-economic goal too, is to perform a cost-utility analysis of the service bundle (IsereADOM) versus conventional 6-month community-based follow-up in a population with heart failure.

Condition or disease Intervention/treatment
Heart Failure Other: Innovative Supported

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Medico-economic Evaluation of a "IsereADOM" Package of Services Versus Conventional Health and Social Monitoring, in the Care of a Population of People With Heart Failure in Isère.
Actual Study Start Date : November 20, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Innovative supported
In addition to usual care, patients benefit from connected tools (overpoise, sphygmomanometer...), physical activity, a strong accompaniment with a referent person
Other: Innovative Supported
addition of connected tools and stronger accompaniment to improve quality of life
No Intervention: conventional supported
Patients benefit from usual care

Primary Outcome Measures :
  1. the effectiveness of a service package compared to conventional follow-up in people with heart failure. [ Time Frame: 6 months ]
    The outcome measure is the number of hospitalization

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient diagnosed with heart failure confirmed by a cardiologist;
  • Patient with functional NYHA II, III, IV staining;
  • Patient domiciled in a geographical area allowing access to the IsèreADOM service package: Grenoble agglomeration, Vercors, Bièvre Valloire, Porte des Alpes;
  • Patient who can be followed regularly for 6 months;
  • Patient who can benefit from RESIC-type health education;
  • Presence of a caregiver referent of proximity (family or other) according to appreciation of the investigating doctor in case of cognitive disorders;
  • Patient affiliated with social security or beneficiary of such a scheme;
  • Patient able to read, write and understand French;
  • Patient having signed informed consent to participate.

Exclusion Criteria:

  • Patient with peritoneal dialysis or haemofiltration;
  • Patient with severe co-morbidity with poor short-term prognosis: mortality <6 months;
  • Patient with future surgical etiologic treatment: prosthetic valve, revascularization procedure, TAVI or MITRACLIP;
  • Patient residing in a nursing home or institution for dependent person;
  • Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all persons protected: pregnant woman, parturient, mother who is breastfeeding, person deprived of liberty by judicial or administrative decision, person subject of a legal protection measure).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03457623

Contact: Marion Proust +33 (0)4 76 76 73 12 mproust@chu-grenoble.fr

Groupe Hospitalier Mutualiste Recruiting
Grenoble, France, 38000
Contact: Marion Proust         
Principal Investigator: Damien GUIJARRO, MD         
CHU Grenoble-Alpes Recruiting
Grenoble, France, 38043
Contact: Marion Proust         
Principal Investigator: Muriel Salvat, MD         
Sponsors and Collaborators
University Hospital, Grenoble
Conseil Départemental de l'Isère
Principal Investigator: Muriel SALVAT, MD CHU Grenoble - Alpes

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69. doi: 10.1093/eurjhf/hfs105. Erratum in: Eur J Heart Fail. 2013 Mar;15(3):361-2.

Responsible Party: University Hospital, Grenoble
ClinicalTrials.gov Identifier: NCT03457623     History of Changes
Other Study ID Numbers: 38RC16.045
First Posted: March 7, 2018    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases